靶向表皮生长因子受体治疗肿瘤(4)
18. Baselga,J; Herbst, R; LoRusso, P; etc al. Continuous administration of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol;19: 177,2000.
19. Laurie, S. A; Miller, V. A; Johnson, D; etc al. Pilot trial of ZD1839 ('Iressa'), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer(NSCLC). Lung Cancer, 29 (Suppl. l): 71, 2000.
20. Miller, V. A; Johnson, D; Heelan, R. T; etc al. A pilot trial demonstrates the safety of ZDI839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol; 21: 326,2001., http://www.100md.com(翁毅敏)
19. Laurie, S. A; Miller, V. A; Johnson, D; etc al. Pilot trial of ZD1839 ('Iressa'), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer(NSCLC). Lung Cancer, 29 (Suppl. l): 71, 2000.
20. Miller, V. A; Johnson, D; Heelan, R. T; etc al. A pilot trial demonstrates the safety of ZDI839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol; 21: 326,2001., http://www.100md.com(翁毅敏)